Summary & Overview
CPT 81208: BCR/ABL1 Atypical Breakpoint Molecular Test
CPT code 81208 covers molecular laboratory testing for BCR/ABL1 fusion genes that arise from atypical breakpoints on chromosome 22. These assays detect and, when quantitative methods are used, measure BCR/ABL1 fusion transcripts outside the common major and minor breakpoint regions. The code matters nationally because detection of atypical BCR/ABL1 variants can affect diagnostic classification, monitoring strategies, and targeted therapy decisions for patients with suspected or known BCR/ABL1–associated hematologic neoplasms.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes coverage and billing considerations across major national payers and Medicare, highlights clinical context for ordering and reporting these specialized molecular tests, and outlines typical sites of service and service type.
Readers will learn: a concise description of the procedure represented by CPT code 81208; which major payers are considered in the national overview; clinical implications of identifying atypical BCR/ABL1 fusions; and where the test is typically performed. Data not available in the input for payer-specific reimbursement rates, associated taxonomies, ICD-10 pairings, or related codes are noted as unavailable in their respective sections.
Billing Code Overview
CPT code 81208 describes laboratory testing to evaluate BCR/ABL1 gene rearrangements occurring on chromosome 22 at atypical breakpoints (breakpoints other than the major and minor breakpoints associated with common translocations). The assay can be qualitative, identifying the presence of BCR/ABL1 fusion variants at these other breakpoints, or quantitative, measuring the amount of each fusion transcript present.
Service type: Molecular diagnostic laboratory procedure
Typical site of service: Clinical molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A 54-year-old patient with suspected chronic myeloid leukemia (CML) presents to a hematology clinic after routine blood work shows leukocytosis and a peripheral smear suspicious for a myeloproliferative disorder. The hematologist orders molecular testing for BCR-ABL1 fusion variants. A peripheral blood sample is collected in EDTA and sent to a molecular diagnostics laboratory. In the lab, a molecular technologist performs a targeted assay to detect BCR-ABL1 gene fusions occurring at breakpoints other than the classic major (p210) and minor (p190) breakpoints; the assay may be qualitative to identify presence of atypical fusion transcripts or quantitative to measure transcript burden for monitoring minimal residual disease. Results are reported to the ordering clinician to guide diagnosis, risk stratification, and targeted therapy decisions. Typical sites of service include hospital outpatient laboratories, independent clinical reference laboratories, and academic medical center molecular pathology laboratories. Turnaround time varies from same-day to several days depending on method (RT-PCR or sequencing) and whether reflex testing is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the interpretive/professional component of the test by a physician or qualified laboratory director. |